Skip to content
Disclosery

Merck & Co., Inc.

Follow

13F filer, CIK 310158, RAHWAY, NJ

Merck & Co., Inc. reported $164,284,061 across 12 holdings for the quarter ended 2025-03-31, in a 13F-HR filed 2025-05-14. Its ten largest share positions make up 99.69% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000064978-25-000005

Period
2025-03-31
Reported value
$164M
Holdings
12
Top 10 weight
99.69%
New
0
Sold out
1

Part of the filer group Merck & Co., Inc.

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
EVAXION BIOTECH A/Sadded+671,847$1.24M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ABSIexited-998,163-$2.62M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2025

Share positions as resolved from 13F-HR 0000064978-25-000005, largest first. % of portfolio is the value over $164,284,061, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
MRNAMODERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 2,308,190 shares; 2025Q1: 2,308,190 shares 2,308,190$65.4M39.83%0Timeline
PSNLPERSONALIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 14,044,943 shares; 2025Q1: 14,044,943 shares 14,044,943$49.3M30.01%0Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 772,165 shares; 2025Q1: 772,165 shares 772,165$21.1M12.86%0Timeline
ENTRADA THERAPEUTICS INCENTRADA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,739,768 shares; 2025Q1: 1,739,768 shares 1,739,768$15.7M9.57%0
ALECALECTOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 3,545,719 shares; 2025Q1: 3,545,719 shares 3,545,719$4.36M2.65%0Timeline
EVAXION BIOTECH A/SEVAXION BIOTECH A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 542,279 shares; 2025Q1: 1,214,126 shares 1,214,126$2.25M1.37%+671,847
SUTRO BIOPHARMA INCSUTRO BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 2,723,509 shares; 2025Q1: 2,723,509 shares 2,723,509$1.77M1.08%0
LAVA THERAPEUTICS NVLAVA THERAPEUTICS NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,149,345 shares; 2025Q1: 1,149,345 shares 1,149,345$1.46M0.89%0
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 93,414 shares; 2025Q1: 93,414 shares 93,414$1.26M0.77%0Timeline
XLOXilio Therapeutics Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,483,758 shares; 2025Q1: 1,483,758 shares 1,483,758$1.07M0.65%0Timeline
CARMCARISMA THERAPEUTICS INC COMQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,473,240 shares; 2025Q1: 1,473,240 shares 1,473,240$457K0.28%0Timeline
NEUPNEUPHORIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 10,027 shares; 2025Q1: 10,027 shares 10,027$57.8K0.04%0Timeline

Sold out in Q1 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ABSIABSCI CORPORATION998,163$2.62Mshares

How Q1 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000064978-25-000005 base2025-05-14acceptance time not in the bulk data set